Search Results

Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that it has entered into a Restructuring Support Agreement with certain funds managed by Highbridge Capital Management, LLC, the Company’s principal lender.

Gamida Cell Ltd. today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024.

Gamida Cell today announced new executive leadership following a successful restructuring transaction (“Transaction”) with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”) on May 24, 2024.

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced it is actively pursuing strategic alternatives in order to maximize value for all stakeholders, focusing on an asset sale, merger or other strategic transaction.

Gamida Cell Ltd. today announced it will present new data on its FDA approved allogeneic stem cell therapy Omisirge at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings.

Gamida Cell Ltd. presented data highlighting its expanded access program for FDA-approved allogeneic stem cell therapy Omisirge® and Phase 1 data for its allogeneic cryopreserved natural killer cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research.

Gamida Cell Ltd today reported financial results for the quarter ended September 30, 2023, and provided a business update.